StockData

Jazz Pharmaceuticals vs Royalty Pharma

JAZZ and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JAZZ and RPRX compare

Royalty Pharma is the larger company, worth 2.5 times as much as Jazz Pharmaceuticals ($39.5B against $15.6B).

On earnings, Royalty Pharma is cheaper: it trades at 39.0× trailing earnings, against 78.4× for Jazz Pharmaceuticals.

Jazz Pharmaceuticals grew revenue faster over the last twelve months (13.5% versus 10.0% for Royalty Pharma).

Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with 4.4% at Jazz Pharmaceuticals.

Royalty Pharma pays a dividend yielding 1.4%; Jazz Pharmaceuticals does not pay one.

Royalty Pharma scores higher on the StockData Score (8 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJAZZRPRX
Size and price
Market cap$15.6B$39.5B
Share price$240.71$68.68
Change, 1 year70.6%75.4%
Change, 5 years94.0%64.0%
Beta (5Y)0.200.04
Employees2,890100
StockData Score
Total score78 (better)
Valuation score00
Growth score22
Performance score3 (better)2
Health score22
Dividend score02 (better)
Valuation
P/E78.4×39.0× (better)
P/S3.3× (better)15.6×
P/B3.7×–
EV/EBITDA43.1×33.5× (better)
P/FCF9.6×–
PEG–0.24
FCF yield10.4%–
Fair value$108.40$45.76
Margin of safety−122%−50.1% (better)
Growth
Revenue growth (TTM)13.5% (better)10.0%
Revenue growth, 5Y average12.5% (better)2.3%
Net income growth (TTM)–−20.4%
EPS growth (TTM)–−19.3%
EPS growth, 5Y average–6.2%
Profitability
Operating margin9.0%59.6% (better)
Net margin4.4%32.1% (better)
FCF margin34.4%–
Return on equity5.1%–
Return on invested capital4.5%–
Financial health
Debt / equity1.33–
Net debt / EBITDA6.375.37 (better)
Interest coverage–4.2×
Current ratio1.822.80 (better)
Altman Z-score1.972.98 (better)
Piotroski F-score45 (better)
Dividends and buybacks
Dividend yield–1.4%
Buyback yield–0.81%
Shareholder yield0.00%2.2% (better)
Ownership
Held by institutions99.2%63.8%
Held by insiders3.4%22.6%
Insider net buying, 12 months−$67.1M (better)−$82.2M
Superinvestors holding12 (better)
Short interest, % of float9.3%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.